Clinical trials: Inflammatory Disorder
Inflammatory Bowel Diseases
Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib
Patients with ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), have been shown to be at increased risk of developing certain infections, such as shingles from the Herpes Zoster (HZ) virus, as a result of their…
- Trial name
- NCT03591770
- Testing
- SHINGRIX
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Boston Medical Center
Colitis, Ulcerative
A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M
IBD98-M-2002 is a phase 2a , Randomized, Double blind, Placebo-controlled of IBD98-M Delayed Release capsules in subjects with Mild to Moderately Ulcerative Colitis to investigate the clinical efficacy of IBD98-M delayed release…
- Trial name
- NCT02493712
- Testing
- High dose, Low dose
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Holy Stone Healthcare Co., Ltd
Ulcerative Colitis
Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately active ulcerative colitis in adult participants.
- Trial name
- GLADIATOR UC (NCT04607837)
- Testing
- Etrasimod
- Where
- 288 sites in United States, Australia and 16 more
- Volunteers
- 234 people
- Sponsor
- Pfizer
Ankylosing Spondylitis
16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
This study will assess the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.
- Trial name
- MEASURE 1 (NCT01358175)
- Testing
- Secukinumab (75 mg), Secukinumab (150 mg)
- Where
- 67 sites in United States, Belgium and 12 more
- Volunteers
- 371 people
- Sponsor
- Novartis Pharmaceuticals
Pelvic Inflammatory Disease
Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan
Azithromycin had a potent in vitro activities and broad spectrum from typical and atypical bacteria to anaerobes. Azithromycin intravenous formulation demonstrated high efficacy and eradication rate in the western clinical…
- Trial name
- NCT00871494
- Testing
- Azithromycin
- Where
- 31 sites in Japan
- Volunteers
- 76 people
- Sponsor
- Pfizer
Ulcerative Colitis
Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy
Evaluation of the intraepithelial neoplasia detection rate in patients with long standing ulcerative colitis undergoing mucosal staining with oral methylene blue MMX tablets prior to colonoscopy.
- Trial name
- NCT01520324
- Testing
- oral delivery mucosal stain
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Cosmo Technologies Ltd
Skin Diseases, Infectious
Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections
The aim of this study is to see the efficacy and safety of BAY1192631 in Japanese patients with methicillin-resistant staphylococcus aureus (MRSA) (skin and soft tissue infections (SSTI) and SSTI-related bacteremia).
- Trial name
- NCT01967225
- Testing
- Tedizolid Phosphate (Sivextro, BAY1192631), Linezolid
- Where
- 46 sites in Japan
- Volunteers
- 125 people
- Sponsor
- Bayer
Pulmonary Disease, Chronic Obstructive
Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)
More patients with chronic obstructive pulmonary disease (COPD) die from cardiovascular disease than direct pulmonary complications.
- Trial name
- NCT01398943
- Testing
- Tetrahydrobiopterin (BH4), Antioxidant Cocktail
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Augusta University
Colitis, Ulcerative
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- ASTRO (NCT05528510)
- Testing
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3
- Where
- 236 sites in United States, Argentina and 23 more
- Volunteers
- 418 people
- Sponsor
- Janssen Research & Development, LLC
Cure Rate
A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection
This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with acute P. falciparum infection after single dose with KAE609 at 75 mg, 150mg, 225mg and 300mg/day
- Trial name
- NCT01860989
- Testing
- KAE609
- Where
- 4 sites in Thailand, Vietnam
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate
The study compared the efficacy and assessed the safety of secukinumab given as 3 intravenous (i.v.) loading doses or weekly sub-cutaneous (s.c.) loading doses, compared to placebo, followed by monthly s.c.
- Trial name
- NCT01359943
- Testing
- secukinumab (AIN457)
- Where
- 39 sites in United States, Bulgaria and 6 more
- Volunteers
- 221 people
- Sponsor
- Novartis Pharmaceuticals
Sepsis, Gastroenteritis
Utility of Ultrasound Assessment of the Inferior Vena Cava in Patients With Sepsis and Dehydration
Conduct a randomized, controlled trial looking at how the use of ultrasound analyzing the inferior vena cava impacts the management and outcomes of pediatric emergency department patients undergoing evaluation and treatment of…
- Conditions
- Sepsis, Gastroenteritis, Dehydration
- Trial name
- NCT02568189
- Testing
- SonoSite Maxx Series Ultrasound System
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Endocarditis, Bacteremia
Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis
This study will compare dalbavancin to standard of care (SOC) antibiotic therapy for the completion of therapy in patients with complicated bacteremia or infective endocarditis.
- Trial name
- NCT03148756
- Testing
- Dalbavancin, Standard of Care
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- AbbVie
Gram-Negative Bacterial Infections, Sepsis
The Effects of Polymyxin-B Protects on Sepsis Induced Kidney Dysfunction: a Randomized Clinical Trial
Aim of the study is to verify whether Polymyxin-B hemoperfusion protects from renal dysfunction in patients with severe sepsis from gram negative infection.
- Trial name
- NCT00490477
- Testing
- Polymyxin -B fiber hemoperfusion system
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- University of Turin, Italy
Colitis, Ulcerative
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)
The purpose of this study is to evaluate: a) the efficacy of ustekinumab dosing in inducing clinical remission, b) safety profile of ustekinumab, and c) ustekinumab exposure (pharmacokinetics [PK]) in pediatric participants with…
- Trial name
- UNIFI Jr (NCT04630028)
- Testing
- Ustekinumab Dose Based on BSA and Body Weight
- Where
- 58 sites in United States, Belgium and 7 more
- Volunteers
- 112 people
- Sponsor
- Janssen Research & Development, LLC
Degenerative Sacroiliitis, Sacroiliac Joint Disruption
Investigation of Sacroiliac Fusion Treatment (INSITE)
The purpose of this study is to compare outcomes when patients with degenerative sacroiliitis (arthritis of the SI joint) and or sacroiliac disruption (abnormal separation or tearing of the sacroiliac joint)undergo either SI…
- Trial name
- INSITE (NCT01681004)
- Testing
- iFuse Implant System, Non-surgical management
- Where
- 19 sites in United States
- Volunteers
- 159 people
- Sponsor
- SI-BONE, Inc.
DeQuervains Tenosynovitis, Lateral Epicondylitis
Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders
The primary objective of this study is to compare local corticosteroid hand and elbow injections to placebo or ketorolac to determine if there is an equal or better reduction of symptoms for common orthopaedic upper extremity…
- Conditions
- DeQuervains Tenosynovitis, Lateral Epicondylitis, Tennis Elbow, Trigger Finger
- Trial name
- NCT02266433
- Testing
- Ketorolac, Dexamethasone
- Where
- United States
- Volunteers
- 245 people
- Sponsor
- NYU Langone Health
Ulcerative Colitis
Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis
The primary objectives of this study are as follows: 1) To evaluate the efficacy of andecaliximab to induce endoscopy, rectal bleeding, and stool frequency (EBS) clinical remission at Week 8 (Cohort 1); 2) To evaluate the…
- Trial name
- NCT02520284
- Testing
- Andecaliximab
- Where
- 87 sites in United States, Australia and 21 more
- Volunteers
- 165 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
The purpose of this study is to find out if spironolactone added to ambrisentan for Pulmonary Arterial Hypertension (PAH) will increase exercise capacity.
- Trial name
- NCT02253394
- Testing
- Ambrisentan plus Spironolactone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Brigham and Women's Hospital
Breast Cancer
Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver…
- Trial name
- NRR (NCT00006110)
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center